509 related articles for article (PubMed ID: 11432358)
21. [A pilot study of TS-1 combined with cisplatin in patients with advanced gastric cancer].
Iwase H; Shimada M; Nakamura M; Iyo T; Nakarai K; Kaida S; Indo T; Okeya M; Mizuno T; Ina K; Kusugami K
Gan To Kagaku Ryoho; 2002 Sep; 29(9):1575-82. PubMed ID: 12355943
[TBL] [Abstract][Full Text] [Related]
22. [Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer].
Yumine K; Kawahara M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():189-92. PubMed ID: 16898000
[TBL] [Abstract][Full Text] [Related]
23. An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma.
Naito S; Tsukamoto T; Usami M; Fujimoto H; Akaza H
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1065-70. PubMed ID: 20157711
[TBL] [Abstract][Full Text] [Related]
24. Alternate-day oral therapy with TS-1 for advanced gastric cancer.
Arai W; Hosoya Y; Hyodo M; Yokoyama T; Hirashima Y; Yasuda Y; Nagai H; Shirasaka T
Int J Clin Oncol; 2004 Jun; 9(3):143-8. PubMed ID: 15221596
[TBL] [Abstract][Full Text] [Related]
25. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Hoff PM; Pazdur R; Benner SE; Canetta R
Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
[TBL] [Abstract][Full Text] [Related]
26. [Phase I study of S-1. S-1 Study Group].
Taguchi T; Inuyama Y; Kanamaru R; Hasegawa K; Akazawa S; Niitani H; Furue H; Kurihara M; Ota K; Suga S; Ariyoshi Y; Takai S; Shimoyama T; Toge T; Takashima S; Sugimachi K; Hara Y; Fujita H; Kimura K; Saito T; Tsukagoshi S; Nakao I
Gan To Kagaku Ryoho; 1997 Dec; 24(15):2253-64. PubMed ID: 9422070
[TBL] [Abstract][Full Text] [Related]
27. [Combination chemotherapy of TS-1 +cisplatin for inoperable gastric cancer].
Koizumi W; Tanabe S; Higuchi K; Sasaki T; Nakayama N; Nagaba S; Azuma M; Shimoda T; Nishimura K; Nakatani K; Saigenji K
Gan To Kagaku Ryoho; 2004 Nov; 31(12):1957-61. PubMed ID: 15570920
[TBL] [Abstract][Full Text] [Related]
28. [Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients].
Arai K; Iwasaki Y; Kimura Y; Takahashi K; Yamaguchi T; Honma S; Takahashi T
Gan To Kagaku Ryoho; 2003 Sep; 30(9):1297-301. PubMed ID: 14518409
[TBL] [Abstract][Full Text] [Related]
29. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
31. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer.
Yamagata S; Nakata B; Hirakawa K
Oncol Rep; 2004 Nov; 12(5):973-8. PubMed ID: 15492780
[TBL] [Abstract][Full Text] [Related]
32. [An early phase II clinical study of S-1 in patients with breast cancer. S-1 Cooperative Study Group (Breast Cancer Working Group)].
Taguchi T; Morimoto K; Horikoshi N; Takashima S; Toge T; Kimura M; Sano M; Aoyama H; Ota J; Noguchi S
Gan To Kagaku Ryoho; 1998 Jun; 25(7):1035-43. PubMed ID: 9644319
[TBL] [Abstract][Full Text] [Related]
33. Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan.
Shirasaka T; Yamamitsu S; Tsuji A; Taguchi T
Invest New Drugs; 2000 Nov; 18(4):315-29. PubMed ID: 11081568
[TBL] [Abstract][Full Text] [Related]
34. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
35. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
[TBL] [Abstract][Full Text] [Related]
36. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients.
Sakata Y; Ohtsu A; Horikoshi N; Sugimachi K; Mitachi Y; Taguchi T
Eur J Cancer; 1998 Oct; 34(11):1715-20. PubMed ID: 9893658
[TBL] [Abstract][Full Text] [Related]
37. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
Cohen SJ; Leichman CG; Yeslow G; Beard M; Proefrock A; Roedig B; Damle B; Letrent SP; DeCillis AP; Meropol NJ
Clin Cancer Res; 2002 Jul; 8(7):2116-22. PubMed ID: 12114411
[TBL] [Abstract][Full Text] [Related]
38. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors.
Hoff PM; Saad ED; Ajani JA; Lassere Y; Wenske C; Medgyesy D; Dwivedy S; Russo M; Pazdur R
Clin Cancer Res; 2003 Jan; 9(1):134-42. PubMed ID: 12538461
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Tominaga K; Higuchi K; Okazaki H; Suto R; Hamaguchi M; Tanigawa T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Oshitani N; Matsumoto T; Arakawa T
Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
[TBL] [Abstract][Full Text] [Related]
40. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
Yoshisue K; Masuda H; Matsushima E; Ikeda K; Nagayama S; Kawaguchi Y
Drug Metab Dispos; 2000 Oct; 28(10):1162-7. PubMed ID: 10997934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
